12:00 AM
 | 
Nov 25, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Bexsero regulatory update

FDA approved an extended treatment IND from the U.S. Centers for Disease Control to use Bexsero from Novartis to combat an outbreak of meningococcal disease caused by Neisseria meningitides...

Read the full 125 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >